TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1467095

Group type: EXPERIMENTAL
Intervention: Extradural infusion of 0.15% bupivacaine with 0.01% diamorphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extradural bolus diamorphine 3.6 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patient-controlled i.v. administration of diamorphine at a maximum rate of 1 mg per 5 min
Number of subjects: 0
Study: 6379507

Group type: EXPERIMENTAL
Intervention: Bovine brain gangliosides, 40 mg daily intramuscular injections for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30409751

Group type: EXPERIMENTAL
Intervention: Smartphone-based intervention for weight management
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (general health information)
Number of subjects: 40
Study: 29320927

Group type: EXPERIMENTAL
Intervention: Microcuff tracheal tubes
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional uncuffed tubes
Number of subjects: 80
Study: 26854833

Group type: EXPERIMENTAL
Intervention: Individualized (problem-adapted) written recommendations
Number of subjects: 337

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 337
Study: 24424425

Group type: EXPERIMENTAL
Intervention: Modafinil (400mg/d)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa (800/200mg/d)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Naltrexone (50mg/d)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 22242600

Group type: COMPARATOR
Intervention: Direct composite resin (positive control)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Partial coverage with composite resin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional full coverage with composite resin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Modified full coverage with composite resin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Untreated (negative control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 100
Study: 20953063

Group type: EXPERIMENTAL
Intervention: Aerobic training on a cycloergometer, 3 times a week, at 70‐80% of the maximum tolerated heart rate (HR) (training group, n=60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (n=60)
Number of subjects: 120
Study: 17432998

Group type: EXPERIMENTAL
Intervention: Standardized recommendations to reduce exposure to allergens (dust mite, pets, food allergens) and passive smoking
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: 4 weeks longer breastfeeding
Number of subjects: 222
Study: 16372814

Group type: EXPERIMENTAL
Intervention: Dexamethasone-cyclophosphamide (D/C) pulse therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Methylprednisolone-azathioprine (M/A) therapy
Number of subjects: 22
Study: 12063318

Group type: EXPERIMENTAL
Intervention: REM sleep
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Non-REM sleep
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Short- and intermediate-term intervals
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: All groups during REM sleep
Number of subjects: 32
Study: 10215093

Group type: EXPERIMENTAL
Intervention: Cognitive reaction-time tasks, semantic memory task, memory comparison task, mental rotation task, mirror reading task
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cognitive reaction-time tasks with opportunities for procedural learning
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tasks varying difficulty of access to procedural memory
Number of subjects: 12
Study: 9485967

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.0625% with fentanyl 2.5 micrograms.ml‐1 at a rate of 10‐12 ml.h‐1
Number of subjects: 2

Group type: COMPARATOR
Intervention: Bupivacaine 0.125% alone
Number of subjects: 2
Study: 2166716

Group type: EXPERIMENTAL
Intervention: Soluble dietary fibre supplement (7 g/day for 2 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 7106067

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 233 μg/m3 sulfuric acid
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 418 μg/m3 sulfuric acid
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 939 μg/m3 sulfuric acid
Number of subjects: 11
Study: 30632152

Group type: EXPERIMENTAL
Intervention: Amniotic membrane (AM)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Temporalis fascia (control)
Number of subjects: 148
Study: 28063158

Group type: EXPERIMENTAL
Intervention: Volitionally induced muscle cramps (VIMCs)
Number of subjects: 15
Study: 26963842

Group type: EXPERIMENTAL
Intervention: Brexpiprazole 3 mg/day
Number of subjects: 97

Group type: COMPARATOR
Intervention: Aripiprazole 15 mg/day
Number of subjects: 97
Study: 25206295

Group type: EXPERIMENTAL
Intervention: Probiotic combination (Lactobacillus acidophilus ATCC 700396 and Bifidobacterium lactis ATCC SD5220)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotic combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21999398

Group type: EXPERIMENTAL
Intervention: DHA supplementation (3 grams/day, 90 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 20397080

Group type: EXPERIMENTAL
Intervention: 6% Cellulose Sulfate microbicide gel
Number of subjects: 0
Study: 17917625

Group type: EXPERIMENTAL
Intervention: Oral administration of prednisolone for 6 weeks followed by topical application of 2% minoxidil for 14 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy of prednisolone and minoxidil
Number of subjects: 0
Study: 16086923

Group type: EXPERIMENTAL
Intervention: TnT-positive group (TnT > or = 0.1 ng/mL)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: TnT-positive group (TnT > or = 0.03 ng/mL)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: TnT-positive group (TnT > or = 0.01 ng/mL)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: TnT-positive group
Number of subjects: 113
Study: 12161826

Group type: EXPERIMENTAL
Intervention: Center-based exercise (endurance, strength, balance, flexibility) 3 times weekly for months 1 to 6, once weekly for months 7 to 12 with home exercise 2 sessions a week, and at home only for months 13 to 18
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Center-based exercise
Number of subjects: 155

Group type: COMPARATOR
Intervention: Home endurance exercise (control)
Number of subjects: 155
Study: 10444056

Group type: EXPERIMENTAL
Intervention: 0.3% topical ciprofloxacin presoaked in disposable soft contact lenses for 10-12 hours, applied for 3 hours (Group A)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 0.3% topical ciprofloxacin presoaked in disposable soft contact lenses for 10-12 hours, applied for 5-6 hours (Group B)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 0.3% topical ciprofloxacin presoaked in disposable soft contact lenses for 10-12 hours, applied for 8-12 hours (Group C)
Number of subjects: 3
Study: 7484829

Group type: COMPARATOR
Intervention: Pravastatin treatment
Number of subjects: 6000
Study: 2399774

Group type: EXPERIMENTAL
Intervention: Surgery and chemotherapy (combination of bleomycin, vincristine, mitomycin-C, and cisplatin; later carboplatin and bleomycin)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 32

Group type: COMPARATOR
Intervention: Surgery and postoperative radiotherapy
Number of subjects: 32
Study: 7365120

Group type: EXPERIMENTAL
Intervention: Biofeedback training (contingent feedback)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Noncontingent biofeedback training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Analogous external placebo (brain wave stimulator)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Concentration exercise (internal attribution)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Combination of brain wave stimulator and concentration exercise
Number of subjects: 50

Group type: COMPARATOR
Intervention: Unaided efforts
Number of subjects: 50
Study: 30829698

Group type: EXPERIMENTAL
Intervention: Laparoscopic distal gastrectomy (LDG)
Number of subjects: 1011

Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 1011
Study: 28843184

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 0
Study: 25997818

Group type: EXPERIMENTAL
Intervention: Ganetespib (150 mg/m² on days 1 and 15) in combination with Docetaxel (75 mg/m² on day 1)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m² on day 1) alone
Number of subjects: 385
Study: 23245197

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) treatment
Number of subjects: 93

Group type: COMPARATOR
Intervention: No Contingency Management (non-CM)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Pretreatment delay discounting
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Pretreatment discounting
Number of subjects: 93
Study: 21982465

Group type: EXPERIMENTAL
Intervention: 1-day cefazolin prophylaxis
Number of subjects: 231

Group type: COMPARATOR
Intervention: 3-day cefazolin prophylaxis
Number of subjects: 231
Study: 19167238

Group type: EXPERIMENTAL
Intervention: EPO (15,000 IE of rHuEPO)
Number of subjects: 3

Group type: COMPARATOR
Intervention: LPS alone
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: EPO and LPS
Number of subjects: 3
Study: 17123158

Group type: EXPERIMENTAL
Intervention: Race-based peremptory challenges
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Justification of peremptory challenges
Number of subjects: 0
Study: 15552197

Group type: EXPERIMENTAL
Intervention: Topical NSAIDs for three days preoperatively
Number of subjects: 0
Study: 11515642

Group type: EXPERIMENTAL
Intervention: sorbitol/carbamide gum
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: sorbitol gum
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: xylitol gum
Number of subjects: 602

Group type: COMPARATOR
Intervention: control gum
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: no gum
Number of subjects: 602
Study: 9609411

Group type: EXPERIMENTAL
Intervention: ATIII (total dose 24000 units)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ATIII
Number of subjects: 120
Study: 7924773

Group type: EXPERIMENTAL
Intervention: HbA1c of the dense erythrocytes in mothers of heavy-for-dates infants (mean +/- SD; 5.86 +/- 0.68%)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Maternal body mass index (BMI) in mothers of heavy-for-dates infants (mean +/- SD; 26.5 +/- 2.9 kg/m2)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Occurrence of high levels of HbA1c of the dense erythrocytes
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Maternal BMI
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Glycated albumin levels
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Correlation between high levels of HbA1c of the dense erythrocytes and maternal obesity
Number of subjects: 59
Study: 2369792

Group type: EXPERIMENTAL
Intervention: Dextrose hydration (group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hypertonic saline (group 2)
Number of subjects: 20
Study: 367043

Group type: EXPERIMENTAL
Intervention: Clonidine 0.05 mg twice daily
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Tyramine 125 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (for tyramine trial)
Number of subjects: 49
Study: 30783069

Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive-Behavioural Therapy (iCBT), 8-week therapist-guided
Number of subjects: 174

Group type: COMPARATOR
Intervention: Waitlist Control Group (CG)
Number of subjects: 174
Study: 27797015

Group type: EXPERIMENTAL
Intervention: Perseverative cognition
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Problem solving
Number of subjects: 56

Group type: COMPARATOR
Intervention: Mind wandering
Number of subjects: 56
Study: 26446153

Group type: EXPERIMENTAL
Intervention: Interactive training sessions for nursing staff (two 4-hour sessions) to recognize potentially harmful medications
Number of subjects: 227

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 227
Study: 23495767

Group type: EXPERIMENTAL
Intervention: Ambu aScope
Number of subjects: 60

Group type: COMPARATOR
Intervention: Olympus BF videobronchoscope
Number of subjects: 60
Study: 21826782

Group type: EXPERIMENTAL
Intervention: Hydroxyurea and phlebotomy for 30 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transfusions and chelation (standard therapy)
Number of subjects: 0
Study: 19299471

Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir plus nevirapine (LPV/r+NVP)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (delayed switching for 24 weeks)
Number of subjects: 101
Study: 17229772

Group type: EXPERIMENTAL
Intervention: Venlafaxine 37.5 mg twice a day for 4 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clonidine 0.075 mg twice a day for 4 weeks
Number of subjects: 80
Study: 15049169

Group type: EXPERIMENTAL
Intervention: Mild hypothermia
Number of subjects: 0
Study: 11279398

Group type: EXPERIMENTAL
Intervention: Balneotherapy with arsenical-ferruginous water
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo vaginal suppositories
Number of subjects: 30
Study: 9623518

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 13
Study: 7930697

Group type: EXPERIMENTAL
Intervention: RT-PCR assay for MCV RNA on blood samples from case-patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: RT-PCR assay for MCV RNA on PBMC RNA preparations
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nucleotide sequencing of G2 and S segment amplimers
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Testing of convalescent samples
Number of subjects: 20
Study: 2491460

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg o.m.
Number of subjects: 98

Group type: COMPARATOR
Intervention: Cimetidine 800 mg nocte
Number of subjects: 98
Study: 31904841

Group type: EXPERIMENTAL
Intervention: High-resource telecare intervention
Number of subjects: 25

Group type: COMPARATOR
Intervention: Low-resource telecare intervention
Number of subjects: 25
Study: 30418116

Group type: EXPERIMENTAL
Intervention: Medical Cannabis Therapy (MCT) after 3 months of Standardised Analgesic Therapy (SAT)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Medical Cannabis Therapy (MCT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standardised Analgesic Therapy (SAT)
Number of subjects: 31
Study: 28196254

Group type: EXPERIMENTAL
Intervention: Scalp cooling (n=119)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control (n=63)
Number of subjects: 182
Study: 25968836

Group type: EXPERIMENTAL
Intervention: Intravaginal DHEA (6.5 mg daily for 52 weeks)
Number of subjects: 668

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 668
Study: 23679290

Group type: EXPERIMENTAL
Intervention: Lifestyle practices including smoking, alcohol consumption, exercise, sun protection, and fruit consumption.
Number of subjects: 1100
Study: 21728418

Group type: EXPERIMENTAL
Intervention: Workplace Triple P (WPTP)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Waitlist Control (WLC)
Number of subjects: 121
Study: 19779467

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1,500 mg per day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 31
Study: 16540815

Group type: EXPERIMENTAL
Intervention: quetiapine (400‐600 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: divalproex (serum level 80‐120 microg/mL)
Number of subjects: 50
Study: 14709947

Group type: EXPERIMENTAL
Intervention: Fluvoxamine CR
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 11460608

Group type: EXPERIMENTAL
Intervention: Test Dentifrice containing pyrophosphate, tripolyphosphate and a copolymer in a 0.243% sodium fluoride/silica base
Number of subjects: 91

Group type: COMPARATOR
Intervention: Positive Control Dentifrice containing tetrapotassium pyrophosphate, disodium pyrophosphate and tetrasodium pyrophosphate in a 0.243% sodium fluoride/silica base
Number of subjects: 91
Study: 9510662

Group type: EXPERIMENTAL
Intervention: CPAP breathing at 10 cmH2O for 25 minutes
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: BiPAP breathing at 10/4 cmH2O for 25 minutes
Number of subjects: 9
Study: 8238157

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Magnesium sulfate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Terbutaline
Number of subjects: 80
Study: 3936908

Group type: EXPERIMENTAL
Intervention: Oral L-carnitine supplementation (70 mumol/l/kg/24 h in 24 mL of 5% dextrose) for seven days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo supplementation (dextrose 5%, 24 cc/24 h) for seven days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral L-carnitine supplementation
Number of subjects: 12
Study: 31079938

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg plus bevacizumab 15 mg/kg intravenously once every 3 weeks
Number of subjects: 915

Group type: COMPARATOR
Intervention: Sunitinib 50 mg orally once daily for 4 weeks on, 2 weeks off
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus bevacizumab
Number of subjects: 915

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 915
Study: 28704309

Group type: EXPERIMENTAL
Intervention: ECC/ECC
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CON/CON
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 40
Study: 27089460

Group type: EXPERIMENTAL
Intervention: Higher aerobic fitness levels
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Increases in aerobic fitness
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Higher levels of fitness
Number of subjects: 290
Study: 25122645

Group type: EXPERIMENTAL
Intervention: 0.25, 0.5, and 1.0 L of milk
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Milk exosomes added to cell culture media
Number of subjects: 5

Group type: COMPARATOR
Intervention: Milk miRNA-depleted diet for 4 weeks
Number of subjects: 5

Group type: COMPARATOR
Intervention: Broccoli sprout feeding studies
Number of subjects: 5
Study: 22425473

Group type: EXPERIMENTAL
Intervention: EP and ToM video-based training, n=27
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard social cognitive rehabilitation treatment, n=24
Number of subjects: 52

Group type: COMPARATOR
Intervention: Time-matched control group, n=24
Number of subjects: 52
Study: 18819958

Group type: EXPERIMENTAL
Intervention: Foot orthoses fitted by a physiotherapist
Number of subjects: 42
Study: 18700378

Group type: EXPERIMENTAL
Intervention: Resonance Frequency Analysis (Osstell)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Damping Capacity Assessment (Periotest)
Number of subjects: 65
Study: 16379551

Group type: EXPERIMENTAL
Intervention: Casein hydrolysate prepared with Aspergillus oryzae protease
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 12456597

Group type: EXPERIMENTAL
Intervention: Human albumin administration
Number of subjects: 378

Group type: COMPARATOR
Intervention: Placebo or no treatment (Control)
Number of subjects: 378
Study: 10468903

Group type: EXPERIMENTAL
Intervention: MK-677 (25 mg/day; n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 24
Study: 8612318

Group type: EXPERIMENTAL
Intervention: Epirubicin 75 mg/m2
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Epirubicin 90 mg/m2
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Epirubicin 105 mg/m2
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Epirubicin 120 mg/m2
Number of subjects: 18
Study: 2007742

Group type: EXPERIMENTAL
Intervention: 0.5 mg Beclomethasone dipropionate (BD) enemas for 28 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: 5 mg Betamethasone phosphate (BP) enemas for 28 days
Number of subjects: 32
Study: 6347921

Group type: EXPERIMENTAL
Intervention: Sulconazole nitrate cream 1%
Number of subjects: 96

Group type: COMPARATOR
Intervention: Miconazole nitrate cream 2% (twice daily application)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Sulconazole nitrate cream 1% (bid)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 96
Study: 31331390

Group type: EXPERIMENTAL
Intervention: H. pylori sero-positive
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: Atrophic gastritis (PGI < 30 μg/L or PGI: PGII < 3.0)
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: Past H. pylori infection (sero-negative to H. pylori IgG antibody) with atrophic gastritis
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: Adjustment for age, sex, and religiosity
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 934
Study: 28121288

Group type: EXPERIMENTAL
Intervention: Personalised and tailored letter from the general practitioner and an invitation to a taster session.
Number of subjects: 4384

Group type: COMPARATOR
Intervention: Standard generic letter from the general practice advertising the local SSS.
Number of subjects: 4384

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of the intervention.
Number of subjects: 4384
Study: 26931302

Group type: EXPERIMENTAL
Intervention: High dairy protein, moderate CHO diet (40% CHO: 30% protein: 30% fat; ∼4 dairy servings)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: High dairy protein, high CHO diet (55% CHO: 30% protein: 15% fat; ∼4 dairy servings)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control diet (55% CHO: 15% protein: 30% fat; ∼1 dairy serving)
Number of subjects: 111
Study: 24488157

Group type: EXPERIMENTAL
Intervention: Focused Playtime Intervention (FPI)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 70
Study: 22943685

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of mesenchymal stem cells (MSCs) [(4.9 ± 1.7) × 10(8), n = 17]
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of mononuclear stem cells (MNCs) [(5.1 ± 2.0) × 10(8), n = 16]
Number of subjects: 53

Group type: COMPARATOR
Intervention: Normal saline (control group, n = 20)
Number of subjects: 53